Praxis Precision Advances CNS Disorder Therapies

Praxis Precision Medicines ( (PRAX) ) has shared an announcement.

Praxis Precision Medicines is advancing its CNS disorder therapies, with promising developments in its late-stage drugs: relutrigine for developmental and epileptic encephalopathies, ulixacaltamide for essential tremor, and vormatrigine for epilepsy. The company is expanding its EMBOLD study and planning new trials, supported by strong financials and a focus on precision medicine. These efforts highlight significant progress towards potentially transformative treatments in the neurological space.

See more insights into PRAX stock on TipRanks’ Stock Analysis page.